Low-Dose Atropine for Myopia: Evidence and Prescribing Decisions

Identify the exact treatment question

“Does low-dose atropine work?” is too broad to answer well. The concentration, formulation, population, outcome, comparator and follow-up all matter. Prevention before onset is also a different question from slowing progression in established myopia.

Begin with the child's findings and the decision under consideration. Review previous treatment, relevant health information, visual needs, practical support and the ability to obtain a reliable supply. A published concentration does not by itself determine an individual prescription.

This guide is for professional evidence appraisal and care planning. It does not give a child-specific dose, recommend home dilution or supply a universal escalation schedule. Prescribing and monitoring require the treating clinician, applicable product information and local requirements.

Keep the intended outcome clear in the record. A plan to manage progression should include how response, visual function and tolerability will be assessed. The family also needs to understand that trial averages do not guarantee an individual result.

Read the one-year LAMP comparison within its boundaries

The randomized LAMP trial compared 0.05%, 0.025% and 0.01% atropine with placebo in 438 Hong Kong children aged 4–12. At one year, the reported mean axial-length increases were 0.20, 0.29, 0.36 and 0.41 mm respectively. The corresponding standard deviations were 0.25, 0.20, 0.29 and 0.22 mm. ^[1]

Those values describe that specific outcome and interval. The values are group means, with variation among participants. They are not individual growth targets, head-to-head comparisons with optical treatments or proof that one concentration is the best choice for every population.

Keep the visual-function and adverse-effect assessment with the efficacy discussion. A treatment decision needs more than selecting the shortest bar. The actual preparation, clinical suitability and family's experience remain part of prescribing.

Do not merge the trial's different outcomes into one percentage. Refractive change and axial growth have different units, and a relative reduction depends on the comparator and time period used.

Include evidence that does not give the same answer

A U.S. PEDIG trial studied 0.01% atropine against placebo over two years in 187 children aged 5–12. It did not find slowing of refractive progression or axial elongation with that preparation in that setting. That result challenges the idea that all products labeled 0.01% should be expected to reproduce the same effect. ^[2]

The 2026 CHAMP-UK trial reported a different result. It randomized 289 children aged 6–12 to preserved 0.01% atropine or placebo for two years. The reported mean between-group differences favored atropine by 0.33 D for refractive progression and 0.14 mm for axial length, with 95% confidence intervals of 0.17–0.49 D and 0.07–0.21 mm respectively. ^[3]

These studies cannot be turned into a simple conclusion that country or ethnicity explains the difference. Products, protocols, participants, adherence and other study features can differ. Examine the methods before attributing a cause.

The comparison board keeps each study's concentration, population and interval visible. It is an evidence-reading aid, not a prescribing algorithm. A later positive study does not erase an earlier negative one, and an earlier negative study does not settle every subsequent formulation.

Separate the concentration from the product

A concentration states an amount of active ingredient relative to the preparation. It does not describe every relevant feature of that preparation, such as excipients, preservation, packaging, stability or supply controls.

Verify the exact product and its authorization for the intended use in the relevant jurisdiction. Do not infer that a myopia indication is authorized simply because another atropine product or concentration has an approval for a different purpose.

Compounded medicines are not FDA-approved. The FDA explains that it does not review their safety, effectiveness or quality before marketing in the way it reviews approved drugs. Compounding can meet particular medical needs, but it is not the same as an approved generic product. ^[5]

When compounding is used within applicable requirements, communicate the exact prescription and clarify storage, beyond-use information and supply questions with the responsible pharmacy. Do not substitute a generalized online storage rule for the dispensed preparation's instructions. Families should not make their own dilutions.

The fictional pharmacy scene illustrates coordination around a preparation. It does not depict a marketed product, a prescription or endorsement by the people shown.

Turn evidence into an informed discussion

Explain why an option is being considered, what relevant studies found, where results differ and what is unknown for the individual child. Keep alternatives and practical demands visible.

Discuss symptoms and tolerability in terms the family can recognize. The prescriber should provide specific advice about potential visual effects, adverse reactions, accidental exposure, missed doses and when to seek help. A general article should not replace those instructions.

AHRQ's informed-choice approach supports checking understanding throughout the discussion. Ask the family to explain the plan and important help routes in their own words. Correct a misunderstanding before assuming a signed form reflects informed understanding. ^[6]

Record the clinical reasoning and the family's preferences. Avoid presenting the selection as a guaranteed result or implying that the same concentration is appropriate whenever a prescription changes. The treatment plan should remain open to review based on reliable measurements and the child's experience.

Set monitoring before the first prescription is filled

Establish the baseline information and follow-up plan needed to assess the question being treated. Include refractive and axial measurements where appropriate and available, visual function, ocular health and relevant symptoms.

Record the measurement methods and actual dates. Interpret change with age, prior trajectory, treatment use, product changes and the interval between visits. A single reading should not trigger an automatic concentration change without clinical assessment.

Ask how the routine is happening. A delayed refill, unclear instructions or a product change may affect interpretation. Document these facts rather than assuming either perfect use or a lack of motivation.

The monitoring guide provides a framework for checking comparability and trends. The family organizer helps households keep instructions and supplies connected without modifying the prescription.

Plan a review of continuation and stopping

Do not let “use this until further notice” become the only long-term plan. Discuss when the clinician will review continued treatment, what information will inform a decision and how monitoring will continue if the plan changes.

The five-year LAMP extension studied longer-term treatment and a defined retreatment approach after cessation. Its later phases included treatment switches and a study-specific protocol, so the five-year findings should not be read as five years of an unchanged original placebo-controlled comparison. ^[4]

A study's stopping or retreatment threshold is not automatically a universal clinical rule. The clinician should consider the child's findings, the preparation, evidence, preferences and safety when deciding how to proceed.

Give clear instructions for the period after a change. Families should know the next review, what to report, whether another modality is being used and who owns resupply or discontinuation communication. Do not leave them to invent a taper or restart plan from an online chart.

Keep the pharmacy and clinical records consistent

Write the prescription and associated instructions clearly enough for the dispensing team to identify the intended preparation. Confirm questions rather than assuming a product described with the same concentration is identical to the one discussed.

When a preparation, source or packaging changes, review the implications and update the family instructions. Retain relevant dates and product information in the clinical record so that an unexpected response can be investigated.

Ask families to contact the team if the label differs from what they expected or if they cannot obtain the prescribed product. A supply problem should lead to advice, not an improvised substitute, another person's medicine or a homemade solution.

Use a closed-loop handoff for an agreed change. The clinician, pharmacy and family should have a consistent account of what is being used and what happens to the previous instructions. Preserve the distinction between a proposed discussion and a prescription that has actually changed.

Maintain a current evidence and authorization check

Atropine research and regulatory status can change. This edition incorporates the named studies available for review on October 22, 2026. It does not claim that one database search resolves every local prescribing or authorization question.

Check the current product information and relevant regulator at the time of prescribing. Update evidence summaries when a material trial, safety finding or authorization changes the discussion, rather than adding a new percentage to an old chart without reviewing its meaning.

The American Academy of Orthokeratology and Myopia Control (AAOMC) offers professional education and resources. Its inclusion supports readers finding further learning; it does not imply endorsement of this article or a particular preparation. ^[7]

Use the worksheet to review the exact product, evidence question, counseling, monitoring and continuation plan. It is a professional discussion aid, not an individualized prescription or dose calculator.